List of Excipients in Branded Drug TRULICITY

Trulicity Excipient Strategy and Commercial Opportunities

Last updated: September 20, 2026

Trulicity (dulaglutide) is a once-weekly injectable GLP-1 receptor agonist marketed by Eli Lilly. Its commercial formulation uses a small, conventional excipient system: citrate buffering, mannitol for tonicity and stabilization, polysorbate 80 as a surfactant, and water for injection. The main commercial opportunities are not commodity excipient substitution. They are formulation support, device compatibility, container-closure systems, biosimilar-enabling technologies, analytical services, and manufacturing platforms that reduce aggregation, adsorption, particulates, and cold-chain cost.

Trulicity remains a high-value product, with 2024 global revenue of approximately $5.4 billion despite competitive pressure from Mounjaro and Zepbound.[1] Its formulation and delivery system create technical barriers for follow-on products, but the public label does not establish that every listed excipient is separately protected by a Trulicity-specific patent.

What excipients are used in Trulicity?

The approved Trulicity formulation contains dulaglutide in an aqueous, buffered solution. The principal excipients identified in the U.S. prescribing information are:

Component	Function	Commercial relevance
Citric acid	Buffer component and pH control	Controls protein stability and injection tolerability
Sodium citrate	Buffer component	Maintains formulation pH during storage
Mannitol	Tonicity agent and stabilizer	Supports osmolality and may reduce protein instability
Polysorbate 80	Surfactant	Limits interfacial adsorption and agitation-related aggregation
Water for injection	Vehicle	Sterile aqueous delivery medium

The product is supplied in single-dose, prefilled pens containing 0.75 mg, 1.5 mg, 3 mg, or 4.5 mg dulaglutide in 0.5 mL of solution. The label identifies a formulation pH of approximately 6.0 to 6.5.[2]

Trulicity does not use a preservative for multidose vial protection because each pen is intended for single-dose administration. That design reduces preservative-related tolerability and compatibility issues but increases dependence on sterile manufacturing, container closure integrity, and device reliability.

How does the Trulicity formulation work?

Dulaglutide is a fusion protein composed of modified GLP-1 sequences linked to a modified human immunoglobulin G4 Fc fragment. Its large molecular structure and long systemic half-life create formulation risks that differ from those of small-molecule injectables.[3]

The excipient system addresses four main risks:

1. Protein aggregation caused by temperature, agitation, or air-liquid interfaces.
2. Adsorption to manufacturing equipment, syringes, and device-contact surfaces.
3. Loss of potency during refrigerated storage and distribution.
4. Injection-volume and osmolality constraints in a fixed-dose pen.

Polysorbate 80 is particularly relevant because proteins can adsorb to hydrophobic surfaces and interfaces. Surfactants can reduce that interaction, although polysorbates can themselves undergo oxidation or hydrolysis, producing degradation products that may affect protein quality. This creates an analytical and supplier-control opportunity around peroxide levels, fatty-acid composition, hydrolysis products, and lot-to-lot consistency.

Mannitol contributes to tonicity and can support protein stability. It also creates potential risks related to crystallization, phase behavior, and concentration changes during freezing or temperature excursions. The citrate system provides pH control, but citrate concentration and pH must be balanced against protein charge, aggregation, and injection tolerability.

What formulation patents protect Trulicity?

The principal intellectual-property position for Trulicity is expected to center on dulaglutide composition-of-matter, sequence, fusion-protein architecture, manufacturing methods, and specific pharmaceutical compositions. The public FDA label does not map individual excipients to individual patents.

A core U.S. patent associated with dulaglutide is U.S. Patent No. 8,377,849, assigned to Eli Lilly and Company, covering GLP-1-related compounds and compositions. Public patent databases associate the patent family with dulaglutide-related subject matter and a patent-term expiration in 2027, subject to regulatory patent-term adjustment or extension and the scope of issued claims.[4]

Additional continuation and related patent families may cover:

• Dulaglutide sequence and fusion-protein structures.
• Host-cell expression and purification methods.
• Pharmaceutical compositions containing dulaglutide.
• Stabilized protein formulations.
• Prefilled pen and delivery-device configurations.
• Manufacturing and fill-finish processes.

A formulation supplier should not assume that use of citrate, mannitol, or polysorbate 80 alone infringes a Lilly patent. Freedom-to-operate analysis must focus on the exact claim language, including concentration ranges, pH, protein concentration, stability limitations, device features, and manufacturing steps.

When does Trulicity lose exclusivity?

Trulicity’s key exclusivity dates depend on the distinction between regulatory exclusivity and patent protection.

Protection	Relevant date or status
FDA approval	September 18, 2014
New chemical entity exclusivity	Approximately four years from approval, ending in 2018
Core patent protection	Publicly associated with patents expiring around 2027, subject to applicable adjustments
Formulation and device protection	May extend beyond core composition patents if valid and enforceable
Biosimilar or follow-on competition	Timing depends on product classification, pathway, patents, and regulatory litigation

The four-year new chemical entity period has expired. The practical exclusivity barrier is therefore patent-based and depends on the Orange Book record, patent-term adjustments, regulatory certifications, litigation, and settlement terms.

Trulicity is marketed under NDA 125469. Because it is a complex recombinant fusion protein, follow-on competition may face more technical and regulatory complexity than a conventional small-molecule ANDA. A follow-on sponsor may pursue a 505(b)(2) strategy where legally available, while a biological-product strategy may depend on FDA classification and statutory pathway analysis.

What is the Orange Book status of Trulicity?

Trulicity is listed by FDA under NDA 125469. The Orange Book should be treated as the controlling source for current listed patents, expiration dates, pediatric extensions, and any changes to the patent record.[5]

A commercial diligence review should examine:

• Patent numbers listed against each dulaglutide strength.
• Expiration dates and patent-term adjustments.
• Whether listed patents cover the active ingredient, formulation, method of use, or device.
• Any certifications submitted by abbreviated applicants.
• Patent-listing changes and FDA delistings.
• Whether the listed claims are relevant to a proposed formulation or delivery system.

The Orange Book does not provide a complete map of all trade secrets, manufacturing know-how, supplier specifications, or non-listed device rights. It also does not establish that every excipient combination used in Trulicity is proprietary.

Which companies are challenging Trulicity exclusivity?

Publicly visible competitive pressure comes primarily from other incretin therapies rather than an established commercial generic or biosimilar Trulicity launch.

The principal competitors are:

Product	Company	Active ingredient	Competitive effect
Mounjaro	Eli Lilly	Tirzepatide	Weekly injectable dual GIP/GLP-1 agonist
Zepbound	Eli Lilly	Tirzepatide	Obesity indication and demand migration
Ozempic	Novo Nordisk	Semaglutide	Weekly GLP-1 injectable
Wegovy	Novo Nordisk	Semaglutide	Obesity indication
Rybelsus	Novo Nordisk	Oral semaglutide	Oral alternative to injectable therapy
Victoza and Saxenda	Novo Nordisk	Liraglutide	Earlier-generation GLP-1 competition

No publicly established commercial biosimilar or generic dulaglutide launch should be assumed solely because the core patent approaches expiration. Regulatory pathway, analytical similarity, manufacturing capacity, litigation, and device replication remain material barriers.

What biosimilar risks affect Trulicity?

Dulaglutide is a large, structurally complex protein. A follow-on product must address primary sequence, higher-order structure, glycosylation, aggregation, potency, immunogenicity, impurities, and stability.

The principal technical barriers are:

• Demonstrating analytical similarity to a proprietary fusion protein.
• Matching biological activity across relevant assays.
• Controlling high-molecular-weight species and subvisible particles.
• Establishing comparable degradation pathways.
• Reproducing the performance of a single-dose prefilled pen.
• Generating sufficient clinical or pharmacology data under the applicable FDA pathway.
• Securing a reliable supply of high-quality polysorbate, mannitol, citrate, and container components.

Excipients generally do not create the same exclusivity barrier as the active protein. They can still create development risk. A different surfactant, buffer, or tonicity agent may alter aggregation, subvisible particle formation, injection force, or immunogenicity. A follow-on sponsor may therefore choose the same qualitative excipient system to reduce analytical and clinical comparability risk, subject to freedom-to-operate and supply availability.

What commercial opportunities exist in Trulicity excipients?

Excipient supply and quality systems

The largest near-term opportunity is qualified supply rather than novel chemistry. Suppliers can compete on:

• Low-peroxide polysorbate 80.
• Reduced-variability pharmaceutical-grade mannitol.
• Low-endotoxin citrate salts.
• Documentation supporting biologics manufacturing.
• Global dual sourcing.
• Stability data under refrigerated and excursion conditions.
• Extractables and leachables packages.

Polysorbate 80 is the most technically sensitive component. A supplier with strong control over oxidation, hydrolysis, fatty-acid profile, and trace impurities can offer value beyond price.

Formulation development

Contract development organizations can support:

• Accelerated and real-time stability programs.
• Surfactant concentration optimization.
• Freeze-thaw and agitation studies.
• Protein adsorption testing.
• Subvisible-particle characterization.
• Container-closure compatibility.
• Comparative characterization for follow-on dulaglutide programs.

The strongest commercial position is likely to come from integrated formulation and analytical packages rather than a single excipient.

Device and container-closure systems

Trulicity is delivered through a single-dose pen. Commercial opportunities include:

• Low-sorption primary containers.
• Silicone-oil control.
• Needle and elastomer compatibility.
• Autoinjector mechanisms.
• Human-factors engineering.
• Device-based dose confirmation.
• Pen recycling and lower-material designs.
• Assembly and fill-finish services.

Device compatibility can remain a meaningful barrier after active-ingredient patents expire. A technically equivalent formulation in a different device may require separate usability, reliability, and regulatory work.

Cold-chain reduction

A formulation that tolerates wider temperature excursions could reduce distribution losses and expand access. Opportunities include:

• Higher thermal stability.
• Reduced aggregation after agitation.
• Improved tolerance to short-term temperature excursions.
• Lyophilized or concentrated presentations.
• Alternative buffers or stabilizers.

A dry powder or lyophilized dulaglutide product would require major development work because reconstitution, dose accuracy, patient usability, and device integration would change. It is a longer-term platform opportunity, not a simple excipient substitution.

How strong is the Trulicity patent estate?

The estate is strongest around the dulaglutide molecule and related protein architecture. Formulation and device claims can add launch risk, but their strength depends on claim scope, validity, written description, enablement, and infringement facts.

For excipient-focused companies, the key distinction is between:

• Patents claiming dulaglutide itself.
• Patents claiming a composition containing dulaglutide within defined ranges.
• Patents claiming a delivery device.
• Trade secrets covering process controls and specifications.
• Unprotected formulation know-how that can be independently developed.

A supplier selling a standard pharmacopeial excipient normally faces lower direct patent risk than a company developing a copy of the complete Trulicity formulation and pen. The risk increases when a product reproduces specific concentration ranges, pH values, device geometry, or stability limitations claimed in an issued patent.

What generic launch risks exist after core patent expiry?

A post-expiry launch could follow several scenarios:

Scenario	Likely commercial effect
No immediate follow-on approval	Lilly retains substantial share while competitors focus on tirzepatide and semaglutide
One approved follow-on product	Price pressure begins selectively, depending on interchangeability and payer policy
Multiple follow-on products	Greater rebate competition and possible rapid net-price erosion
Device or formulation litigation	Launch delay despite active-ingredient patent expiry
Supply-constrained launch	Limited initial impact and premium pricing
Successful differentiated presentation	Potentially higher-value product despite active-ingredient competition

The commercial impact will depend on whether a follow-on product is substitutable at the pharmacy level, whether it uses an equivalent pen, and whether payers prefer lower-cost dulaglutide or higher-efficacy competing incretin products.

What is the revenue exposure for Eli Lilly?

Trulicity remains a multibillion-dollar product, but Lilly’s portfolio reduces its dependence on the product. In 2024, Lilly reported approximately $5.4 billion in Trulicity revenue, while Mounjaro and Zepbound became major growth drivers.[1]

The main revenue risks are:

• Share migration to tirzepatide.
• Competition from semaglutide.
• Pricing and rebate pressure.
• Manufacturing allocation across incretin products.
• Patent or regulatory challenges.
• Future follow-on entry after core exclusivity expires.

For excipient and manufacturing companies, the product’s revenue scale supports continued demand for qualified materials even if Trulicity volume declines. The more durable opportunity is serving the broader GLP-1 and protein-injectable market with platform technologies that can be used across multiple products.

Key Takeaways

• Trulicity uses citrate buffer, mannitol, polysorbate 80, and water for injection.
• The formulation is an aqueous, single-dose, prefilled-pen product with a pH of approximately 6.0 to 6.5.
• Polysorbate quality, protein aggregation, particulates, container compatibility, and cold-chain stability are the main technical issues.
• Core dulaglutide patent protection is publicly associated with expiration around 2027, subject to applicable patent-term adjustments and other rights.
• The Orange Book, not the product label alone, controls the current listed-patent analysis.
• No established commercial generic or biosimilar Trulicity launch should be assumed.
• The strongest commercial opportunities are qualified excipient supply, formulation analytics, device compatibility, fill-finish, and biosimilar-enabling platforms.
• Trulicity’s revenue exposure is material, but Lilly’s Mounjaro and Zepbound franchises reduce dependence on dulaglutide.

FAQs

Is polysorbate 80 essential to the Trulicity formulation?

The label identifies polysorbate 80 as an excipient, and its likely role is to reduce protein adsorption and interfacial aggregation. A substitute surfactant could require extensive comparability, stability, immunogenicity, and regulatory work.

Can a company sell the same excipients used in Trulicity?

Yes. Selling pharmaceutical-grade citrate, mannitol, or polysorbate 80 does not by itself establish infringement. The relevant analysis concerns the claims of issued patents and the customer’s complete formulation, process, and device.

Is Trulicity a biologic or a conventional generic drug?

Dulaglutide is a complex recombinant fusion protein. Follow-on development is more technically demanding than conventional small-molecule generic development, and the available FDA pathway must be assessed against the product’s regulatory classification and patent record.

Could a preservative-free Trulicity alternative have commercial value?

Yes, but Trulicity is already a single-dose product without a conventional multidose preservative requirement. The more significant opportunities are improved stability, reduced particulates, lower injection force, and device or container performance.

Which excipient has the greatest strategic importance for follow-on dulaglutide?

Polysorbate 80 is likely the most sensitive because its quality attributes can affect aggregation, particles, and protein stability. Mannitol and citrate remain important for tonicity, pH, and overall formulation robustness.

References

1. Eli Lilly and Company. (2025). 2024 annual report. Eli Lilly and Company.

2. U.S. Food and Drug Administration. (2024). Trulicity (dulaglutide) prescribing information. FDA.

3. U.S. Food and Drug Administration. (2014). Multidisciplinary review and approval package for Trulicity, NDA 125469. FDA.

4. U.S. Patent No. 8,377,849. (2013). GLP-1 compounds. United States Patent and Trademark Office.

5. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.